Brief: AstraZeneca & Daiichi Sankyo announce clinical collaboration with Summit Therapeutics
02/10/2026 07:41
BRIEF-AstraZeneca & Daiichi Sankyo announce clinical collaboration with Summit Therapeutics Oct 2 (Reuters) - AstraZeneca PLC AZN.L:
ASTRAZENECA PLC - AZ & DS COLLABORATION WITH SUMMIT FOR DATROWAY
ASTRAZENECA - PHASE III TRIAL TO BEGIN IN FIRST-LINE TRIPLE-NEGATIVE BREAST CANCER
ASTRAZENECA - EACH COMPANY TO CONTRIBUTE MEDICINE FOR COMBINATION TRIALS
ASTRAZENECA - CO, DAIICHI SANKYO, SUMMIT TO CONTRIBUTE TO TRIAL COSTS AND RETAIN RIGHTS
Source text: ID:nRSB3872Xa
Further company coverage: AZN.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsAstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
Early US flu season, current strain may signal risk for younger people; doctors urge shots
AstraZeneca partners with Oracle for AI-driven clinical trials
Factbox: Pharma sector doubles down on AI to slash costs, timelines